Alder Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Alder specializes in therapeutic monoclonal antibodies. The company was founded by Randall C. Schatzman, John A. Latham, and Mark J. Litton in 2004. The CEO is Dr. Randy Schatzman. Alder went public in May 2014.
Their best known drug is the monoclonal antibody eptinezumab, which is now in its second phase III trial for migraine prevention. They have a second monoclonal antibody drug for migraine, ALD-1910, currently in pre-clinical development. Alder licensed clazakizumab, previously ALD-518, an anti-IL-6 monoclonal antibody to Vitaeris, Inc. for worldwide marketing.